Compass Therapeutics, Inc.: Form 10-K for the period ended Mar 31, 2020
Filed with the SEC on Jun 8, 2020 and accepted by EDGAR at Jun 8, 2020, 20:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2019-04-01 to 2020-03-31 | −$32.1k | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-04-01 to 2020-03-31 | $5.4k | us-gaap:InterestExpense |
| Net income | 12 months2019-04-01 to 2020-03-31 | −$37.5k | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-04-01 to 2020-03-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-04-01 to 2020-03-31 | −$32.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-03-31 | $3.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $3.7k | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $3.7k | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $111.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $111.8k | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-03-31 | −$108.1k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-20-014390. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.